Chemical Component Summary

Identifiers4,6-dioxo-1,3,5-triazinane-2-carboxylic acid
FormulaC4 H5 N3 O4
Molecular Weight159.1
Isomeric SMILESC1(NC(=O)NC(=O)N1)C(=O)O

Chemical Details

Formal Charge0
Atom Count16
Chiral Atom Count0
Bond Count16
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB03209 
Groups approved
DescriptionOteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno". The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary for continued cancer growth. Oteracil's main role within Teysuno is to reduce the activity of 5-FU within normal gastrointestinal mucosa, and therefore reduce's gastrointestinal toxicity [L933]. It functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU.
  • Oteracil potassium
  • Oxonic Acid
  • Oxonate
  • 5-azaorotic acid
  • Allantoxanic acid
Brand NamesTeysuno
IndicationOteracil is used as an adjunct to antineoplastic therapy. When used within the product Teysuno, oteracil is indicated for the treatment of adults with advanced gastric (stomach) cancer when given in combination with cisplatin.
CAS number937-13-3

Related Resource References

Resource NameReference
PubChem 100562